Achieve Life Sciences: CFO Benjamin Halladay received 400,000 shares

What happened Benjamin Halladay, chief financial officer, received two derivative awards from Achieve Life Sciences totaling 400,000 shares on Oct 5, 2026. The filing lists two entries of 200,000 shares each, transaction code A (award/grant), at $0.00 per share (total value $0.00).

Key details

• Transaction date and price: Oct 5, 2026; two awards of 200,000 shares each at $0.00 per share.
• Nature of awards: both are reported as derivative securities. One entry is accompanied by a vesting schedule consistent with an option award (footnote F1); the other is reported as RSUs (footnotes F2 and F3).
• Shares owned after the transaction: not stated in this filing.
• Relevant footnotes from the filing:
  • F1: The option will vest as to 1/4 of the total award on the first anniversary of Oct 5, 2026, and thereafter in substantially equal monthly installments over 36 months, subject to the reporting person’s provision of service on each vesting date.
  • F2: Each RSU represents a contingent right to receive one share of the issuer’s common stock at settlement.
  • F3: The RSUs will vest as to 1/4 of the total award on each of Oct 5, 2027, Oct 5, 2028, Oct 5, 2029 and Oct 5, 2030, subject to the reporting person’s provision of service on each vesting date.
• Filing date and reporting period: Form 4 filed Oct 6, 2026; period of report Oct 5, 2026. The filing does not indicate a late filing.

Why it may matter

• These entries are grants/awards (derivative securities), not open-market purchases or sales.
• One award appears to be an option-type grant with time-based vesting (F1); the other is an RSU grant with multi-year vesting dates (F2/F3).
• A filing does not show why the insider traded or why the company acted.